Program
teplizumab
Also written as “Teplizumab”, “teplizumab 1 mg/mL” and “Teplizumab Herold Regimen”.
Its studies are mostly in Diabetes Mellitus, Type 1 · Psoriasis, led by 3 companies.
Drug pageTeplizumab: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 52 open or running | phase 4since Feb 13, 2023 | Mar 13, 2019 | Mar 6, 2028phase 2 · NCT06791291 |
| MacroGenicsits history only | 30 open or running | phase 3since Oct 7, 2006 | Oct 7, 2006 | none ahead |
| Precigen Actobio T1D | 10 open or running | phase 2since Nov 8, 2018 | Nov 8, 2018 | none ahead |
Also a collaborator on its studies: Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Precigen Actobio T1D only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 8, 2018First study: phase 2 study in Diabetes type1First studyNCT03751007 · 45 enrolled · United States, Belgium
TargetBeta
“T-cell surface glycoprotein CD3 epsilon chain other”ChEMBL 37, by rule
Other programs on CD3E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etentamig | AbbVie | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| cevostamab | Hoffmann-La Roche | phase 3 | 8 |
| pasritamig | Johnson & Johnson | phase 3 | 5 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
Studies
The one study Precigen Actobio T1D leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03751007Diabetes type1 · United States, Belgium | 2 | Completed | Oct 13, 2021 | 45 |
How it is read
Names in the registry
- “Teplizumab”, 4 entries
- “teplizumab”, 3 entries
- “teplizumab 1 mg/mL”, 1 entry
- “Teplizumab Herold Regimen”, 1 entry
- “Teplizumab 33.3% Herold Regimen”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 8 studies
- Psoriasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.